

In case of discrepancy between the Norwegian language original text and the English language translation, the Norwegian text shall prevail

**PROTOKOLL FRA
ORDINÆR GENERALFORSAMLING**

THOR MEDICAL ASA

Den 24. april 2025 kl. 14.00 ble det avholdt ordinær generalforsamling i Thor Medical ASA ("**Selskapet**") i Advokatfirmaet Selmer AS' lokaler i Ruseløkkveien 14, 0251 Oslo.

Styrets leder Ludvik Sandnes åpnet møtet og tok opp fortegnelse over møtende aksjeeiere og fullmakter, samt forhåndsstemmer, inntatt i Vedlegg 1. 174 314 280 aksjer var representert, tilsvarende ca. 55,44 % av totalt antall utestående aksjer og stemmer.

Til behandling forelå:

1 Valg av møteleder og en person til å medundertegne protokollen

Generalforsamlingen fattet følgende vedtak:

Jon Fredrik Johansen velges som møteleder, og Ludvik Sandvik velges til å medundertegne protokollen.

2 Godkjenning av innkalling og dagsorden

Generalforsamlingen fattet følgende vedtak:

Innkalling og dagsorden godkjennes.

3 Godkjennelse av årsregnskapet og styrets årsberetning for Thor Medical ASA og konsernet for regnskapsåret 2024, herunder disponeringen av årets resultat, samt behandling av redegjørelse for foretaksstyring

Møteleder viste til Selskapets årsregnskap, årsberetning og konsernregnskap for 2024, herunder redegjørelse for foretaksstyring etter regnskapsloven § 3-3b og redegjørelse

**MINUTES FROM
ORDINARY GENERAL MEETING**

THOR MEDICAL ASA

On 24 April 2025 at 14.00 hours (CEST), the ordinary general meeting was held in Thor Medical ASA (the "**Company**") in Advokatfirmaet Selmer AS' offices in Ruseløkkveien 14, 0251 Oslo.

The chairman of the board, Ludvik Sandnes, opened the meeting and registered the attendance of shareholders present and proxies, as well as advance votes, as listed in Appendix 1. 174,314,280 shares were represented, equivalent to approximately 55.44% of the total number of outstanding shares and votes.

The following matters were on the agenda:

1 Election of a chairman of the meeting and a person to co-sign the minutes

The general meeting made the following resolution:

Jon Fredrik Johansen is elected as chairman of the meeting, and Ludvik Sandnes is elected to co-sign the minutes.

2 Approval of notice and agenda

The general meeting made the following resolution:

Notice and agenda are approved.

3 Approval of the annual accounts and the directors' annual report for Thor Medical ASA and the group for the financial year 2024, including allocation of the result of the year, as well as consideration of the statement on corporate governance

The chairman of the meeting referred to the Company's annual accounts, annual report and consolidated accounts for 2024, including a report on corporate governance

for samfunnsansvar etter regnskapsloven § 3-3c, samt revisors beretning.

Generalforsamlingen fattet følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Styrets forslag til årsregnskap, herunder konsernregnskapet og årsberetning for regnskapsåret 2024 godkjennes.

4 Rådgivende avstemning over Selskapets lederlønsrapport

Møteleder viste til styrets rapport om godtgjørelse av Selskapets ledende personer ("**Lederlønsrapporten**") utarbeidet i henhold til allmennaksjeloven § 6-16-b.

Generalforsamlingen behandlet Lederlønsrapporten i henhold til allmennaksjeloven § 5-6 (4) ved rådgivende avstemning.

Resultat fra avstemningen ble notert for protokollen, slik det fremgår av Vedlegg 2:

5 Godkjennelse av revisors godtgjørelse

Møteleder viste til styrets forslag.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Revisjonsgodtgjørelse til Ernst & Young AS for 2024 på NOK 730 000 eks. mva. godkjennes.

6 Fastsettelse av godtgjørelse til styrets medlemmer

Møteleder viste til valgkomiteens innstilling til fastsettelse av godtgjørelse til styrets medlemmer, herunder utstedelse av RSUer til styrets medlemmer.

pursuant to section 3-3b of the Norwegian Accounting Act and a report on corporate social responsibility pursuant to section 3-3c of the Norwegian Accounting Act, as well as the auditor's report.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

The board of directors' proposal for the annual accounts, including the consolidated accounts and the annual report for the financial year 2024 are approved.

4 Advisory vote on the Company's remuneration report

The chairman of the meeting referred to the board of director's report on the remuneration of the Company's senior executives (the "**Remuneration report**") prepared in accordance with section 6-16b of the Norwegian Public Limited Liability Companies Act.

The general meeting processed the Remuneration report by advisory vote, pursuant to section 5-6 (4) of the Norwegian Public Limited Companies Act

The results from the advisory vote were recorded in the minutes, as set out in Appendix 2:

5 Approval of the auditor's fee

The chairman of the meeting referred to the board of director's proposal.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

The audit fee for Ernst & Young AS for 2024, amounting to NOK 730,000 excluding VAT, is approved.

6 Determination of remuneration for the members of the board of directors

The chairman of the meeting referred to the nomination committee's recommendation for determination of remuneration to the members of the board of directors, including issuance of RSUs to the members of the board of directors.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Valgkomiteens forslag godkjennes.

7 Fastsettelse av godtgjørelse til valgkomiteens medlemmer

Møteleder viste til valgkomiteens innstilling til fastsettelse av godtgjørelse til valgkomiteens medlemmer.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Medlemmene av Selskapets valgkomite skal motta følgende honorarer for perioden fra den ordinære generalforsamlingen 2025 til den ordinære generalforsamlingen i 2026:

- Valgkomiteens leder: NOK 50 000 per år
- Øvrige medlemmer: NOK 40 000 per år

8 Fullmakt til styret til å forhøye aksjekapitalen i henhold til Selskapets incentivprogram

Møteleder viste til styret forslag.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

- 1. I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til, i en eller flere omganger, å forhøye Selskapets aksjekapital med inntil NOK 2 300 000.*
- 2. Fullmakten kan benyttes til utstedelse av aksjer ved utøvelse av opsjoner/tegningsretter tildelt under Selskapets incentivprogram.*

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

The nomination committee's proposal is approved.

7 Determination of remuneration for the members of the Nomination Committee

The chairman of the meeting referred to the nomination committee's recommendation for the determination of remuneration to the members of the nomination committee.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

The members of the Company's nomination committee shall receive the following fees for the period starting at the annual general meeting 2025 until the annual general meeting in 2026:

- Chairman of the election committee: NOK 50,000 per year
- Other members: NOK 40,000 per year

8 Authorisation to the Board to increase the share capital in connection with the Company's incentive program

The chairman of the meeting referred to the board of directors' proposal.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

- 1. Pursuant to Section 10-14 of the Norwegian Public Limited Companies Act, the Board is authorised to, in one or more occurrences, increase the Company's share capital by up to NOK 2,300,000.*
- 2. The authorisation may be used to issue shares at exercise of options/subscription rights awarded under the Company's incentive program.*

3. Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2026, likevel ikke lenger enn til 30. juni 2026.
4. Aksjonærenes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.
5. Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger mv, jf. allmennaksjeloven § 10-2.
6. Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter allmennaksjeloven § 13-5.

9 Fullmakt til styret til å forhøye aksjekapitalen i tilknytning til utøvelse av RSUer

Møteleder viste til styrets forslag.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

1. I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til, i en eller flere omganger, å forhøye Selskapets aksjekapital med inntil NOK 400 000.
2. Fullmakten kan bare benyttes til utstedelse av aksjer til Selskapets styremedlemmer ved utøvelse av tildelte RSUer.
3. Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2026, likevel ikke lenger enn til 30. juni 2026.
4. Aksjonærenes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.

3. The authorisation is valid until the annual general meeting in 2026, but no longer than 30 June 2026.
4. The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.
5. The authorisation does not comprise share capital increases against contribution in kind, cf. Section 10-2 of the Norwegian Public Limited Companies Act.
6. The authorisation does not comprise share capital increase in connection with mergers pursuant to Section 13-5 of the Norwegian Public Limited Companies Act.

9 Authorisation to the Board to increase the share capital in connection with the exercise of RSUs

The chairman of the meeting referred to the board of directors' proposal.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

1. Pursuant to Section 10-14 of the Norwegian Public Limited Companies Act, the Board is authorised to, in one or more occurrences, increase the Company's share capital by up to NOK 400 000.
2. The authorisation may only be used to issue shares to members of the Company's Board upon exercise of awarded RSUs.
3. The authorisation is valid until the annual general meeting in 2026, but no longer than 30 June 2026.
4. The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.

5. Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger mv. men kan benyttes ved motregning av krav på styregodtgjørelse, jf. allmennaksjeloven § 10-2.
6. Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter allmennaksjeloven § 13-5.

10 Fullmakt til styret til å forhøye aksjekapitalen med inntil 20% for andre angitte formål

Møteleder viste til styrets forslag.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

1. I henhold til allmennaksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital, i en eller flere omganger, med inntil NOK 12 576 340,84.
2. Fullmakten kan benyttes til å styrke Selskapets egenkapital, generelle forretningsmessige formål, herunder men ikke begrenset til finansiering av oppkjøp av andre selskaper, virksomheter eller eiendeler herunder for utstedelse av vederlagsaksjer i forbindelse med overnevnte transaksjoner.
3. Fullmakten gjelder frem til Selskapets ordinære generalforsamling i 2026, likevel ikke lenger enn til 30. juni 2026.
4. Aksjonærenes fortrinnsrett til de nye aksjene etter allmennaksjeloven § 10-4 kan fravikes.
5. Fullmakten omfatter kapitalforhøyelse mot innskudd i penger og i andre eiendeler enn

5. The authorisation does not comprise share capital increases against contribution in kind but may be used for setting of claims for board remuneration, cf. Section 10-2 of the Norwegian Public Limited Companies Act.
6. The authorisation does not comprise share capital increase in connection with mergers pursuant to Section 13-5 of the Norwegian Public Limited Companies Act.

10 Authorisation to the Board to increase the share capital by up to 20% for other specified purposes

The chairman of the board referred to the board of directors' proposal.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

1. Pursuant to Section 10-14 of the Norwegian Public Limited Companies Act, the Board is granted an authorisation to increase the Company's share capital, in one or more occurrences, by up to NOK 12,576,340.84.
2. The authorisation may be used to strengthen the Company's equity, for general corporate purposes, including but not limited to financing of acquisitions of other companies, businesses or assets, including issuance of consideration shares in connection with the above-mentioned transactions.
3. The authorisation is valid until the Company's annual general meeting in 2026, but no longer than 30 June 2026.
4. The shareholders' preferential right to the new shares pursuant to Section 10-4 of the Norwegian Public Limited Companies Act may be deviated from.
5. The authorisation comprises share capital increases against contribution in cash and

penges og rett til å pådra Selskapet særlige forpliktelser mv, jf. allmennaksjeloven § 10-2.

6. *Fullmakten omfatter beslutning om fusjon i henhold til allmennaksjeloven § 13-5.*
7. *Med virkning fra tidspunktet for registrering av denne fullmakten i Foretaksregisteret, erstatter denne fullmakten alle tidligere utstedte styrefullmakter til aksjekapitalforhøyelse.*

11 Valg av medlemmer til styret

Møteleder viste til valgkomiteens innstilling.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Ludvik Sandnes fratrer som styremedlem. Ann Gidner, Thomas Ramdahl og Jens Gisle Schnelle velges som nye styremedlemmer. John Andersen Jr. velges som styrets leder.

Styret består således av:

- *John Andersen Jr., styreleder*
- *Mimi Kristine Berdal, styremedlem*
- *Ann Gidner, styremedlem*
- *Thomas Ramdahl, styremedlem*
- *Jens Gisle Schnelle, styremedlem*

12 Valg av revisor

Møteleder viste til styrets innstilling.

Generalforsamlingen fattet deretter følgende vedtak, med stemmegivning slik det fremgår av Vedlegg 2:

Ernst & Young AS, Stortorvet 7, 0155 Oslo, 976 389 387 velges som Selskapets revisor fra og med regnskapsåret som starter 1. januar 2025.

in kind and the right to impose special obligations on the Company etc, cf. Section 10-2 of the Norwegian Public Limited Companies Act.

6. *The authorisation covers resolutions on mergers as provided in Section 13-5 of the Norwegian Public Limited Companies Act.*
7. *With effect from the date when this mandate is registered with the Norwegian Register of Business Enterprises, it replaces all previous mandates to increase the share capital.*

11 Election of members to the Board of Directors

The chairman of the meeting referred to the nomination committee's recommendation.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

Ludvik Sandnes resign as board member. Ann Gidner, Thomas Ramdahl and Jens Gisle Schnelle are elected as new board members. John Andersen Jr. is elected as chairman of the board.

The board of directors thus consists of:

- *John Andersen Jr., chair*
- *Mimi Kristine Berdal, board member*
- *Ann Gidner, board member*
- *Thomas Ramdahl, board member*
- *Jens Gisle Schnelle, board member*

12 Election of auditor

The chairman of the meeting referred to the board of directors' proposal.

The general meeting adopted the following resolutions, with voting as set out in Appendix 2:

Ernst & Young AS, Stortorvet 7, 0155 Oslo, 976 389 387 is elected as the auditor of the Company as of the fiscal year commencing on 1 January 2025.

Ingen andre saker forelå til behandling og møtet ble hevet.

There were no other matters on the agenda and the meeting was adjourned.

Jon Fredrik Johansen

Ludvik Sandnes

Total Represented

ISIN:	N00010597883 Thor Medical ASA
General meeting date:	24/04/2025 14.00
Today:	24.04.2025

Number of persons with voting rights represented/attended : 10

	Number of shares	% sc
Total shares	314,408,521	
- own shares of the company	0	
Total shares with voting rights	314,408,521	
Represented by own shares	100,043,537	31.82 %
Represented by advance vote	8,398,978	2.67 %
Sum own shares	108,442,515	34.49 %
Represented by proxy	52,124,787	16.58 %
Represented by voting instruction	13,746,978	4.37 %
Sum proxy shares	65,871,765	20.95 %
Total represented with voting rights	174,314,280	55.44 %
Total represented by share capital	174,314,280	55.44 %

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

Thor Medical ASA

Attendance List Attendance Thor Medical ASA 24/04/2025

Ref no	First Name	Company/Last name	Repr. by	Participant	Share	Own	Proxy	Total	% sc	% represented	% registered
					Ordinær	8,398,978	0	8,398,978	2.67 %	4.82 %	4.81 %
1491372	Styrets leder, Ludvik Sandnes	eller den han bemyndiger		Proxy Solicitor	Ordinær	0	17,805,451	20,552,429	6.54 %	11.79 %	11.77 %
1491380		SCATEC INNOVATION AS	John Andersen Jr	Share Holder	Ordinær	78,419,309	0	89,419,309	28.44 %	51.30 %	51.20 %
1491398		ROHT INVEST AS	Jørn Aage Johansen	Share Holder	Ordinær	14,194,640	0	14,194,640	4.52 %	8.14 %	8.13 %
1491448	JON MAGNE	ASMYR		Share Holder	Ordinær	5,000,000	0	5,000,000	1.59 %	2.87 %	2.86 %
1491547	JAN-TORE	PEDERSEN		Share Holder	Ordinær	1,502,099	0	1,502,099	0.48 %	0.86 %	0.86 %
1491778	LUDVIK	SANDNES		Share Holder	Ordinær	626,489	0	626,489	0.20 %	0.36 %	0.36 %
1492198		EKORNHUSET AS	Ludvik Sandnes	Share Holder	Ordinær	300,000	0	300,000	0.10 %	0.17 %	0.17 %
1559632	GURI ELLEN	STANGE		Share Holder	Ordinær	1,000	0	1,000	0.00 %	0.00 %	0.00 %
1630128	Jon Magne	Asmyr		Proxy Solicitor	Ordinær	0	33,879,182	33,879,182	10.78 %	19.44 %	19.40 %
1630748	John	Andersen, jr.		Proxy Solicitor	Ordinær	0	440,154	440,154	0.14 %	0.25 %	0.25 %

Protocol for general meeting Thor Medical ASA

ISIN:	<u>N00010597883 Thor Medical ASA</u>
General meeting date:	24/04/2025 14.00
Today:	24.04.2025

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda Item 1 Election of the chairman for the meeting and one person to co-sign the minutes						
Ordinær	174,314,280	0	174,314,280	0	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.44 %	0.00 %	55.44 %	0.00 %	0.00 %	
Total	174,314,280	0	174,314,280	0	0	174,314,280
Agenda item 2 Approval of the notice and the agenda of the meeting						
Ordinær	174,314,280	0	174,314,280	0	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.44 %	0.00 %	55.44 %	0.00 %	0.00 %	
Total	174,314,280	0	174,314,280	0	0	174,314,280
Agenda item 3 Approval of the annual accounts and the directors report						
Ordinær	174,248,280	0	174,248,280	66,000	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.96 %	0.00 %	99.96 %	0.04 %	0.00 %	
total sc in %	55.42 %	0.00 %	55.42 %	0.02 %	0.00 %	
Total	174,248,280	0	174,248,280	66,000	0	174,314,280
Agenda Item 4 Advisory vote on the Company's remuneration report for 2024						
Ordinær	174,188,280	0	174,188,280	126,000	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.93 %	0.00 %	99.93 %	0.07 %	0.00 %	
total sc in %	55.40 %	0.00 %	55.40 %	0.04 %	0.00 %	
Total	174,188,280	0	174,188,280	126,000	0	174,314,280
Agenda item 5 Approval of the auditors fee						
Ordinær	174,239,723	0	174,239,723	74,557	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.96 %	0.00 %	99.96 %	0.04 %	0.00 %	
total sc in %	55.42 %	0.00 %	55.42 %	0.02 %	0.00 %	
Total	174,239,723	0	174,239,723	74,557	0	174,314,280
Agenda item 6 Determination of remuneration to the members of the Board, in accordance with the NominationCommittees proposal						
Ordinær	174,083,068	85,000	174,168,068	146,212	0	174,314,280
votes cast in %	99.95 %	0.05 %		0.00 %		
representation of sc in %	99.87 %	0.05 %	99.92 %	0.08 %	0.00 %	
total sc in %	55.37 %	0.03 %	55.40 %	0.05 %	0.00 %	
Total	174,083,068	85,000	174,168,068	146,212	0	174,314,280
Agenda Item 7 Determination of remuneration to the members of the Nomination Committee, in accordance with theNomination Committee's proposal						
Ordinær	174,092,068	76,000	174,168,068	146,212	0	174,314,280
votes cast in %	99.96 %	0.04 %		0.00 %		
representation of sc in %	99.87 %	0.04 %	99.92 %	0.08 %	0.00 %	
total sc in %	55.37 %	0.02 %	55.40 %	0.05 %	0.00 %	
Total	174,092,068	76,000	174,168,068	146,212	0	174,314,280
Agenda Item 8 Authorisation to the Board to increase the share capital in connection with the Company's incentiveprogram						
Ordinær	174,111,681	82,944	174,194,625	119,655	0	174,314,280
votes cast in %	99.95 %	0.05 %		0.00 %		
representation of sc in %	99.88 %	0.05 %	99.93 %	0.07 %	0.00 %	
total sc in %	55.38 %	0.03 %	55.40 %	0.04 %	0.00 %	
Total	174,111,681	82,944	174,194,625	119,655	0	174,314,280
Agenda item 9 Authorisation to the Board to increase the share capital in connection with the exercise of RSUs						
Ordinær	174,103,953	90,672	174,194,625	119,655	0	174,314,280
votes cast in %	99.95 %	0.05 %		0.00 %		
representation of sc in %	99.88 %	0.05 %	99.93 %	0.07 %	0.00 %	
total sc in %	55.38 %	0.03 %	55.40 %	0.04 %	0.00 %	
Total	174,103,953	90,672	174,194,625	119,655	0	174,314,280

Shares class	For	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 10 Authorisation to the Board to increase the share capital by 20% for other specified purposes						
Ordinær	174,223,608	90,672	174,314,280	0	0	174,314,280
votes cast in %	99.95 %	0.05 %		0.00 %		
representation of sc in %	99.95 %	0.05 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.41 %	0.03 %	55.44 %	0.00 %	0.00 %	
Total	174,223,608	90,672	174,314,280	0	0	174,314,280
Agenda item 11.1 Election of John Andersen as chair of the board						
Ordinær	152,842,121	21,346,159	174,188,280	126,000	0	174,314,280
votes cast in %	87.75 %	12.26 %		0.00 %		
representation of sc in %	87.68 %	12.25 %	99.93 %	0.07 %	0.00 %	
total sc in %	48.61 %	6.79 %	55.40 %	0.04 %	0.00 %	
Total	152,842,121	21,346,159	174,188,280	126,000	0	174,314,280
Agenda item 11.2 Election of Mimi Kristine Berdal as a member of the board						
Ordinær	174,226,384	87,896	174,314,280	0	0	174,314,280
votes cast in %	99.95 %	0.05 %		0.00 %		
representation of sc in %	99.95 %	0.05 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.41 %	0.03 %	55.44 %	0.00 %	0.00 %	
Total	174,226,384	87,896	174,314,280	0	0	174,314,280
Agenda item 11.3 Election of Ann Gidner as a member of the board						
Ordinær	174,248,280	66,000	174,314,280	0	0	174,314,280
votes cast in %	99.96 %	0.04 %		0.00 %		
representation of sc in %	99.96 %	0.04 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.42 %	0.02 %	55.44 %	0.00 %	0.00 %	
Total	174,248,280	66,000	174,314,280	0	0	174,314,280
Agenda item 11.4 Election of Thomas Ramdahl as a member of the board						
Ordinær	174,254,280	60,000	174,314,280	0	0	174,314,280
votes cast in %	99.97 %	0.03 %		0.00 %		
representation of sc in %	99.97 %	0.03 %	100.00 %	0.00 %	0.00 %	
total sc in %	55.42 %	0.02 %	55.44 %	0.00 %	0.00 %	
Total	174,254,280	60,000	174,314,280	0	0	174,314,280
Agenda item 11.5 Election of Jens Gisle Schnelle as a member of the board						
Ordinær	174,227,780	77,500	174,305,280	9,000	0	174,314,280
votes cast in %	99.96 %	0.04 %		0.00 %		
representation of sc in %	99.95 %	0.04 %	100.00 %	0.01 %	0.00 %	
total sc in %	55.41 %	0.03 %	55.44 %	0.00 %	0.00 %	
Total	174,227,780	77,500	174,305,280	9,000	0	174,314,280
Agenda item 12 Election of auditor						
Ordinær	174,299,723	0	174,299,723	14,557	0	174,314,280
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	99.99 %	0.00 %	99.99 %	0.01 %	0.00 %	
total sc in %	55.44 %	0.00 %	55.44 %	0.01 %	0.00 %	
Total	174,299,723	0	174,299,723	14,557	0	174,314,280

Registrar for the company:

NORDEA BANK ABP, FILIAL NORGE

Signature company:

Thor Medical ASA

Share information

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	314,408,521	0.20	62,881,704.20	Yes
Sum:				

§ 5-17 Generally majority requirement
requires majority of the given votes

§ 5-18 Amendment to resolution
Requires two-thirds majority of the given votes
like the issued share capital represented/attended on the general meeting